Targeted inhibitors of JAK2 have been studied and developed, and these drugs can interfere with the JAK2 modeling pathway and inhibit its aberrant activation, resulting in a reduction in the production of inflammatory mediators, alleviation of the inflammatory response, and amelioration of symptoms and disease progression in CD. The gene discussed is JAK2; the disease is Cowden disease.